Serum levels of matrix metalloproteinases: implications in clinical neurology

Area of Science:

• Biochemistry
• Neurology
• Immunology

Background:

• Matrix metalloproteinases (MMPs) are crucial enzymes regulating the extracellular matrix.
• A pathogenic role for MMPs in various neurological disorders is increasingly recognized.
• This review focuses specifically on the serological clinical aspects of MMPs in neurological diseases.

Purpose of the Study:

• To review the clinical significance of serum matrix metalloproteinases in several neurological conditions.
• To highlight the correlation between MMP levels and disease activity, severity, and outcomes.
• To explore the potential pathogenic mechanisms involving MMPs in neurological disorders.

Main Methods:

• Literature review of studies investigating serum MMP levels in neurological diseases.
• Analysis of correlations between specific MMPs (MMP-1, -2, -3, -8, -9, -10) and clinical parameters.
• Focus on serological findings across multiple sclerosis, myasthenia gravis, stroke, ALS, Alzheimer's, migraine, and epilepsy.

Main Results:

• Elevated serum MMP-3 during multiple sclerosis relapses; MMP-8 and -9 correlate with MRI lesions.
• Increased serum MMP-2, -3, and -9 in myasthenia gravis; MMP-9 aids stroke monitoring.
• Higher serum MMP-9 in acute stroke links to infarct volume and severity; lower MMP-3 noted.
• Serum MMP-2 correlates with progression in ALS; MMP-1 and -2 elevated.
• Elevated serum MMP-3, -9, and -10 in Alzheimer's disease; MMP-2 and -9 in migraine.
• MMP-9 implicated in experimental epilepsy pathogenesis.

Conclusions:

• Serum MMP levels serve as potential biomarkers for disease activity and progression in various neurological disorders.
• MMP dysregulation, potentially through extracellular matrix degradation and autoimmunity, contributes to neurological disease pathogenesis.
• Further research into MMPs offers therapeutic targets for neurological conditions.